HomeProductsBioactive CompoundsImmunology & InflammationComplement ReceptorAvacopan
Chemical structure of CAS 1346623-17-3

Avacopan

CAS No.1346623-17-3
MDL No.MFCD28502293
MFC33H35F4N3O2
MW581.60
InChI KeyPUKBOVABABRILL-YZNIXAGQSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1346623-17-3
Product NameAvacopan

Biological Targets

C5AR1

Associated Conditions

microscopic polyangiitis·Granulomatosis with Polyangiitis·hidradenitis suppurativa·anti-neutrophil cytoplasmic antibody-associated vasculitis·liver disease·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Avacopan for the treatment of ANCA-associated vasculitis.

Expert review of clinical immunology • Vol. 17, Issue 7 • 2021
PMID: 34006155DOI: 10.1080/1744666X.2021.1932466

Management of primary vasculitides with biologic and novel small molecule medications.

Current opinion in rheumatology • Vol. 33, Issue 1 • 2021
PMID: 33164993PMC: PMC7813157DOI: 10.1097/BOR.0000000000000756

Avacopan offers alternative to steroids for ANCA-associated vasculitis.

Nature reviews. Rheumatology • Vol. 17, Issue 5 • 2021
PMID: 33846585DOI: 10.1038/s41584-021-00615-0

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.

JMIR research protocols • Vol. 9, Issue 4 • 2020
PMID: 32088663PMC: PMC7175182DOI: 10.2196/16664

Documentation